Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
14C-VX-993 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 14C VX-993 | EXPERIMENTAL | Participants will receive a single oral dose of 14C-VX-993 after an overnight fast of at least 8 hours. |
| Name | Type | Description |
|---|---|---|
| 14C-VX-993 | DRUG | Solution for Oral Administration. |
Key Inclusion Criteria: * Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2), inclusive * A total body weight of more than (\>) 50 kg * Participants must have at least 1 regular bowel movement per day Key Exclusion Criteria: * History of febrile illness or other acute illne...
14C-VX-993 is an investigational small molecule being developed for the treatment of pain. It is currently in Phase 1 clinical development, with a completed study evaluating how the body processes the drug after a single oral dose. The drug is not yet approved and remains under investigation.
14C-VX-993 is being developed by Vertex Pharmaceuticals Incorporated, a biopharmaceutical company traded on the NASDAQ under the ticker symbol VRTX. The company is conducting clinical research to evaluate the drug's pharmacokinetics in healthy volunteers.
14C-VX-993 is in Phase 1 clinical development. A single Phase 1 study has been completed, which evaluated how the body processes the drug after a single oral dose. The drug is investigational and has not been approved by regulatory authorities.
14C-VX-993 has one completed clinical trial, identified as NCT06886269. This Phase 1 study evaluated how the body processes 14C-VX-993 after a single oral dose in healthy male volunteers aged 18 years and older in the United States. The trial enrolled 8 participants.
14C-VX-993 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for pain. A single Phase 1 study has been completed, but the drug remains under investigation and has not been authorized for marketing.